Teva (TEVA) has reportedly won a reinstatement of USD 177mln patent case against Eli Lilly (LLY)

Teva's reinstatement of a USD 177 million patent case against Eli Lilly signals a potential shift in their competitive dynamics within the pharmaceuticals sector.

Newsquawk StaffPublished On the live feed at 7 more headlines followed before this page went public
Newsquawk headlinesUTC

US Treasury to sell USD 13bln of 20-year bonds on April 22nd and USD 26bln of 5-year TIPS on April 23rd; All to settle April 30th

Newsquawk Daily Economic Releases - 17th April 2026

Teva (TEVA) has reportedly won a reinstatement of USD 177mln patent case against Eli Lilly (LLY)

A US insurance programme for ships to transit the Strait of Hormuz is nearly "ready to go", but is still working out security issues, WSJ reports, citing an official; Chubb (CB) will administer the maritime reinsurance program

US Energy Secretary Wright says the US will be taking more measures to keep gasoline prices low

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This outcome could impact investor sentiment towards both companies, possibly moving the needle on Teva's valuation if successful, while creating uncertainties for Eli Lilly. Watch how this plays in the equity markets and the broader pharmaceutical space, especially regarding potential M&A ramifications.

Related headlines

The whole workspace, free to try.

Try it free